New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 1, 2014
10:00 EDTSRPT, BIN, FLML, CWST, SGMO, PZG, FINL, ANET, SCMP, RNA, PTCT, CBAYOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Arista Networks (ANET) initiated with a Neutral at Citigroup... Casella Waste (CWST) initiated with a Hold at Stifel... CymaBay Therapeutics (CBAY) initiated with an Outperform at Cowen... Finish Line (FINL) initiated with a Buy at Jefferies... Flamel Technologies (FLML) initiated with an Outperform at Leerink... PTC Therapeutics (PTCT) initiated with an Outperform at Oppenheimer... Paramount Gold & Silver (PZG) initiated with a Buy at Noble Financial... Progressive Waste (BIN) initiated with a Hold at Stifel... Prosensa (RNA) initiated with an Outperform at Oppenheimer... Sangamo (SGMO) initiated with an Overweight at JPMorgan... Sarepta (SRPT) initiated with an Outperform at Oppenheimer... Sucampo (SCMP) initiated with a Buy at Roth Capital.
News For ANET;CWST;CBAY;FINL;FLML;PTCT;PZG;BIN;RNA;SGMO;SRPT;SCMP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
December 12, 2014
12:02 EDTPTCTPTC Therapeutics Translarna granted orphan drug designation
Subscribe for More Information
10:01 EDTANETOn The Fly: Analyst Initiation Summary
Subscribe for More Information
05:29 EDTANETArista Networks initiated with a Neutral at Goldman
Subscribe for More Information
December 10, 2014
10:27 EDTFLMLFlamel Technologies management to meet with Roth Capital
Subscribe for More Information
08:16 EDTPZGParamount continues to intersect high gold, silver grades at Don Ese
Subscribe for More Information
December 9, 2014
12:22 EDTSGMOPiper Jaffray biopharm analyst holds an analyst/industry conference call
Senior Research Analyst Schimmer, along with Biopharmaceuticals Analyst Breazzano, discuss gene therapy for hemophilia on an Analyst/Industry conference call to be held on December 11 at 10 am.
12:15 EDTPTCTPTC Therapeutics mentioned positively by dealReporter
Subscribe for More Information
December 8, 2014
07:49 EDTANETArista Networks lawsuit not as threatening as believed, says SunTrust
Subscribe for More Information
07:45 EDTFLMLFlamel Technologies price target raised to $29 from $21 at SunTrust
SunTrust increased its price target on Flamel after meeting with the company's CEO, as the firm now expects the company to raise the price of its Bloxiverz drug next year beyond the firm's previous outlook. SunTrust keeps a Buy rating on the shares.
07:28 EDTANETFBN Securities to hold a bus tour
Subscribe for More Information
07:11 EDTSGMOSangamo presents new data for Vivo Protein Replacement Platform
Sangamo announced the presentation of new preclinical data from its proprietary programs for the treatment of lysosomal storage disorders and Shire-partnered hemophilia program. These studies demonstrate the broad applicability of Sangamo's In Vivo Protein Replacement Platform for the potentially curative treatment of such diseases. The data presented at ASH from Sangamo's proprietary IVPRP applications demonstrated the efficient production, secretion and tissue uptake of functional iduronate-2-sulfatase and alpha-L-iduronidase, enzymes that are deficient in the LSDs, Hunter and Hurler's disease, respectively. Data were also presented from Sangamo's partnered program with Shire that demonstrated that therapeutic levels of Factor IX, the human clotting factor that is deficient in hemophilia B, could be generated in a dose-dependent manner in non-human primates. There were no significant alterations in circulating albumin levels. Studies in mice also demonstrated stable Factor IX production from Sangamo's IVPRP for over 1 year.
07:03 EDTANETArista Networks patent resolution likely 2-3 years away, says Citigroup
Subscribe for More Information
December 5, 2014
10:49 EDTANETCisco confirms two patent suits filed against Arista Networks
Subscribe for More Information
10:45 EDTANETCisco files patent infringement complaints against Arista Networks
Subscribe for More Information
December 4, 2014
16:28 EDTCWSTCasella Waste backs operating guidance for next fiscal year
The company reaffirmed guidance for its next full fiscal year, which will run from January 1, 2015 through December 31, 2015, by estimating results in the following ranges: Revenues between $520M-$530M; Adjusted EBITDA between $103M-$107M; and Free Cash Flow between $14M-$18M.
16:27 EDTCWSTCasella Waste backs operating guidance for 8-month transition period
Subscribe for More Information
16:17 EDTCWSTCasella Waste reports Q2 EPS 1c, consensus 1c
Subscribe for More Information
14:42 EDTPTCTPTC Therapeutics off highs following reported NHS halt of Translarna assement
Shares of PTC Therapeutics remain up 17c, or 0.4%, at $47.07 but are below their earlier session highs following a report from The Chronicle that stated NHS England has halted its assessment of whether to fund PTC's Translarna for sufferers of Duchenne muscular dystrophy.
14:11 EDTPTCTNHS halts assement of PTC Therapeutics DMD drug, Chronicle reports
Subscribe for More Information
06:46 EDTPTCTPTC Therapeutics added to Top Picks List at Credit Suisse
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use